Evidence map›Paper›PMID 42836184›Full record

ArticleResearch in pharmaceutical sciences2026

Synthesis, in vitro and in silico evaluation of quinazoline and triazoloquinazoline derivatives as PDE7A inhibitors.

Afaf A El-Malah, Magdy M Gineinah, Maan T Khayat, Thikryat Neamatallah, Amr Sonousi, Zeinab Mahmoud, Rasha A Hassan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Afaf A El-MalahFaculty of Pharmacy, King Abdul Aziz University, Pharmaceutical Chemistry Department, Jeddah, 21589, Saudi Arabia.
Magdy M GineinahFaculty of Pharmacy, King Abdul Aziz University, Pharmaceutical Chemistry Department, Jeddah, 21589, Saudi Arabia.
Maan T KhayatFaculty of Pharmacy, King Abdul Aziz University, Pharmaceutical Chemistry Department, Jeddah, 21589, Saudi Arabia.
Thikryat NeamatallahDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdul Aziz University, Jeddah, 21589, Saudi Arabia.
Amr SonousiDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.
Zeinab MahmoudDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.
Rasha A HassanDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Phosphodiesterase 7A (PDE7A) is an attractive therapeutic target for the treatment of inflammatory, autoimmune, and neurodegenerative disorders through modulation of intracellular cAMP levels. However, the development of highly potent and selective PDE7A inhibitors remains challenging. This study aimed to design, synthesize, and evaluate 2-chloroquinazoline and fused 1,2,4-triazolo[4,3- Experimental approach: A series of 2-chloroquinazoline derivatives Findings/Results: All compounds demonstrated enzyme inhibition ranging from 0.062 to 1.35 μM;. Derivatives Conclusion and implications: Compounds

Indexed as

Molecular dockingMolecular dynamicsPhosphodiesterase 7 inhibitorsQuinazolineTriazolo[4,3-c] quinazoline.

Identifiers

PMID42836184
PMCPMC13637938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.